The Experts below are selected from a list of 75426 Experts worldwide ranked by ideXlab platform
Stefan Stortecky - One of the best experts on this subject based on the ideXlab platform.
-
Local Versus General Anesthesia for Transcatheter Aortic Valve Replacement: A SwissTAVI Registry Analysis
JACC: Cardiovascular Interventions, 2019Co-Authors: Olivier Muller, Stephane Fournier, Thomas Pilgrim, Dik Heg, Stéphane Noble, Raban Jeger, Stefan Toggweiler, Maurizio Taramasso, Stephan Windecker, Stefan StorteckyAbstract:Although general anesthesia (GA) was the preferred anesthetic management during the early transcatheter aortic valve replacement (TAVR) experience, local anesthesia with procedural sedation (LPS) has become more popular. The aim of the present Analysis was to investigate differences in patient and
Alessandro Vivacqua - One of the best experts on this subject based on the ideXlab platform.
-
Outcome-based cost Analysis of transfemoral transcatheter aortic valve replacement using fascia iliaca compartment block and minimalist conscious sedation approach versus general anesthesia.
Journal of the American College of Cardiology, 2017Co-Authors: Wei Lau, Francis Shannon, George S. Hanzel, Marc Sakwa, Amr E. Abbas, Robert D. Safian, Ivan Hanson, Steve Almany, Alessandro VivacquaAbstract:Background: Early studies demonstrated feasibility of minimalist conscious sedation (CS) for Transfemoral (TF) access for transcatheter aortic valve replacement (TAVR). A recent STS-ACC TVT Registry Analysis demonstrated that a CS TF-TAVR has lower mortality, stroke, and shorter length of stay (LOS
Olivier Muller - One of the best experts on this subject based on the ideXlab platform.
-
Local Versus General Anesthesia for Transcatheter Aortic Valve Replacement: A SwissTAVI Registry Analysis
JACC: Cardiovascular Interventions, 2019Co-Authors: Olivier Muller, Stephane Fournier, Thomas Pilgrim, Dik Heg, Stéphane Noble, Raban Jeger, Stefan Toggweiler, Maurizio Taramasso, Stephan Windecker, Stefan StorteckyAbstract:Although general anesthesia (GA) was the preferred anesthetic management during the early transcatheter aortic valve replacement (TAVR) experience, local anesthesia with procedural sedation (LPS) has become more popular. The aim of the present Analysis was to investigate differences in patient and
E.c. Depasquale - One of the best experts on this subject based on the ideXlab platform.
-
Heart Transplantation Outcomes in Patients with Marfan Syndrome: UNOS Registry Analysis.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020Co-Authors: P.a. Genyk, J. Nattiv, G.s. Liu, P. Banankhah, P.a. Kingsford, A.m. Wolfson, D. Vucicevic, A.s. Vaidya, E.c. DepasqualeAbstract:Marfan syndrome (MS) is an autosomal dominant connective tissue disorder that causes a defect in the gene fibrillin-1. MS patients develop advanced cardiomyopathies, in which previous studies have demonstrated the presence of a discrete cardiomyopathy associated with MS. Given the vascular complications associated with MS and unclear impact immunosuppression may have on systemic vascular disease, little evidence guides suitability of patients with MS for heart transplant. We sought to investigate long-term heart transplant outcomes of patients with MS listed in the UNOS Registry. The UNOS database was queried for all cardiac transplants in the Registry from 1987 to 2019 to compare characteristics and outcomes of patients with MS and all other heart transplant patients. Hazard ratios (HR) were calculated using multivariate Cox proportional hazard regression Analysis. Survival curves were generated with Kaplan Meier method. Between 1987 and 2019, 22 patients with MS were listed for a heart transplant with a mean age of 35.0 ± 16.3 years. Most patients were male (73%) and Caucasian (73%). Patients with MS were more likely to have prior cardiac surgery (non-transplant) compared to all other heart transplant patients (54.5% vs. 18.3%, p < 0.001). They were as likely to be on life support, including IABP and VAD, but more likely to be on ventilator support (p=0.029). Mean waitlist time were similar, 94.0 days (MS patients) vs 83.0 days (all other patients, p=0.54). There was no significant difference in ischemic time. Transplant survival outcomes were similar at 150 months post-HT (Figure, p=0.69). Survival of Marfan patients was comparable to non-Marfan patients despite increased surgical complexity and greater association with prior cardiac surgery. While further study is warranted, heart transplant is a suitable treatment option in patients with Marfan syndrome and advanced heart failure. Copyright © 2020. Published by Elsevier Inc.
-
Heart Transplantation Outcomes in Patients with Marfan Syndrome: UNOS Registry Analysis.
The Journal of Heart and Lung Transplantation, 2020Co-Authors: P.a. Genyk, J. Nattiv, G.s. Liu, P. Banankhah, P.a. Kingsford, A.m. Wolfson, D. Vucicevic, A.s. Vaidya, E.c. DepasqualeAbstract:PURPOSE Marfan syndrome (MS) is an autosomal dominant connective tissue disorder that causes a defect in the gene fibrillin-1. MS patients develop advanced cardiomyopathies, in which previous studies have demonstrated the presence of a discrete cardiomyopathy associated with MS. Given the vascular complications associated with MS and unclear impact immunosuppression may have on systemic vascular disease, little evidence guides suitability of patients with MS for heart transplant. We sought to investigate long-term heart transplant outcomes of patients with MS listed in the UNOS Registry. METHODS The UNOS database was queried for all cardiac transplants in the Registry from 1987 to 2019 to compare characteristics and outcomes of patients with MS and all other heart transplant patients. Hazard ratios (HR) were calculated using multivariate Cox proportional hazard regression Analysis. Survival curves were generated with Kaplan Meier method. RESULTS Between 1987 and 2019, 22 patients with MS were listed for a heart transplant with a mean age of 35.0 ± 16.3 years. Most patients were male (73%) and Caucasian (73%). Patients with MS were more likely to have prior cardiac surgery (non-transplant) compared to all other heart transplant patients (54.5% vs. 18.3%, p < 0.001). They were as likely to be on life support, including IABP and VAD, but more likely to be on ventilator support (p=0.029). Mean waitlist time were similar, 94.0 days (MS patients) vs 83.0 days (all other patients, p=0.54). There was no significant difference in ischemic time. Transplant survival outcomes were similar at 150 months post-HT (Figure, p=0.69). CONCLUSION Survival of Marfan patients was comparable to non-Marfan patients despite increased surgical complexity and greater association with prior cardiac surgery. While further study is warranted, heart transplant is a suitable treatment option in patients with Marfan syndrome and advanced heart failure.
Wei Lau - One of the best experts on this subject based on the ideXlab platform.
-
Outcome-based cost Analysis of transfemoral transcatheter aortic valve replacement using fascia iliaca compartment block and minimalist conscious sedation approach versus general anesthesia.
Journal of the American College of Cardiology, 2017Co-Authors: Wei Lau, Francis Shannon, George S. Hanzel, Marc Sakwa, Amr E. Abbas, Robert D. Safian, Ivan Hanson, Steve Almany, Alessandro VivacquaAbstract:Background: Early studies demonstrated feasibility of minimalist conscious sedation (CS) for Transfemoral (TF) access for transcatheter aortic valve replacement (TAVR). A recent STS-ACC TVT Registry Analysis demonstrated that a CS TF-TAVR has lower mortality, stroke, and shorter length of stay (LOS
